Tango Therapeutics reports Q3 2026 results, plans Phase 3 study of vopimetostat-daraxonrasib combo

Tango Therapeutics reported a cash position of $977.5 million as of September 30, 2026, and highlighted Phase 1/2 data for vopimetostat plus daraxonrasib in 2L/3L pancreatic cancer showing an 82% objective response rate and 88% 9-month progression-free survival. The company plans to initiate a registrational Phase 3 study of the combination as front-line treatment in the first half of 2027.

Detected & updated continuously · Source: Nebula